Vocal biomarkers market is estimated to be valued at USD 3,716.8 Mn in 2026 and is expected to reach USD 10,168.7 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 15.5% from 2026 to 2033.
Market Overview
The increasing use of artificial intelligence and advanced speech analytics in the healthcare sector is significantly contributing to the growth of the vocal biomarkers market. Vocal biomarkers enable non-invasive, cost-effective, and remote diagnosis of diverse healthcare issues by analyzing the minute variations in speech patterns, making them highly amenable for the early diagnosis of diseases and for remote patient surveillance on a perpetual basis.
|
Current Events |
and its impact |
|
Regulatory and Healthcare Policy Developments |
|
|
Technological Advancement and AI Innovation |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
By therapeutic application, the psychological disorders segment is expected to account for the highest market share of approximately 35% in 2026, due to its increasing adoption for the diagnosis and measurement of depression, anxiety, stress, and other psychological disorders using vocal biomarkers. With the use of vocal biomarkers, emotional and cognitive states are able to be accessed for remote, real-time, and non-invasive measurement, making this segment more favorable for psychological health measurement.
For instance, in December 2025, Canary Speech introduced Canary Ambient™, a real-time vocal analysis tool designed to monitor verbal aggression and enhance clinician safety, expanding applications of vocal biomarkers beyond traditional diagnostics.
Based on the end-user, the hospitals segment is projected to contribute the largest market share of around 48% by 2026 due to the increasing adoption of vocal biomarker solutions in various clinical applications such as diagnostics and patient monitoring. The rising adoption of vocal tools in hospitals for the early diagnosis of neurological and mental health-related issues and patient monitoring is expected to drive the market growth. Furthermore, the tertiary level of health facilities has better digital infrastructure and investment capabilities and hence is the first preference for the adoption of vocal biomarkers.
For instance, in June 2025, Beyond Verbal entered a strategic collaboration with Mayo Clinic to develop and validate vocal biomarkers for early‑stage Alzheimer’s disease detection, marking a significant clinical deployment of voice‑based diagnostics in hospital‑linked research settings.

To learn more about this report, Download Free Sample
North America is expected to dominate the vocal biomarkers market in 2026, accounting for 40% of the total market share. Factors such as early adopters of AI-based healthcare solutions, incorporation of vocal biomarkers, major players, and investments in digital health infrastructure drive the market in this region.
For instance, in November 2025, Canary Speech, a Utah‑based leader in AI‑powered vocal biomarker technology, received the 2025 North America Technology Innovation Leadership recognition from Frost & Sullivan for its innovation in intelligent vocal biomarker diagnostics.
The Asia Pacific market is expected to be the fastest-growing market because of the rising awareness about the applications of artificial intelligence in the healthcare sector, the growing prevalence of mental health and neurological disorders, the increasing telehealth services, as well as the initiatives by governments such as China, Japan, and Indian governments to adopt digital health.
For instance, in in May 2025, Sonde Health partnered with Saaya Health to integrate its advanced vocal biomarker technology with Saaya’s mental health and wellbeing platform to support comprehensive health tracking and proactive support for large workforces, demonstrating growing adoption of voice‑based health solutions
The U.S. vocal biomarkers market continues to establish its dominance in the industry by forging partnership agreements, participating in clinical pilots, and integrating cutting-edge AI platforms that increase real-world use of voice-based diagnostic and healthcare offerings. For instance, in May 2025, Sonde Health announced a U.S. collaboration with Saaya Health to embed vocal biomarkers into digital wellbeing solutions that support cognitive and mental health monitoring for employers and clinicians.
China’s vocal biomarker industry is rapidly gaining pace as the Chinese medical sector is witnessing a quick transition into the digital world along with an increase in the demand for non-invasive diagnostic procedures for neurological disorders, psychology, as well as monitoring for chronic diseases. Multilingual voice analysis software using AI is also entering the market to meet the linguistic demands of the Chinese population, thus facilitating accessibility for voice diagnostic analysis even in the Chinese dialects.
For instance, In August 2025, AI acoustic voice biomarker research technologies, including AI‑driven analysis of voice features for clinical condition classification (such as benign voice disorders), was published in peer‑reviewed platforms, underscoring China’s involvement in global research advancing voice‑based health diagnostics and signaling broader interest in deploying voice analytics in clinical settings.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3,716.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 15.5% | 2033 Value Projection: | USD 10,168.7 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Beyond Verbal, Inc., Sonde Health Inc., Sharecare, Inc., IBM Corporation, Cogito Corporation, AudEERING, VoiceSense, Winterlight Labs, Ellipsis Health, and Vocalis Health |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The growth of the vocal biomarkers market is driven by increasing integration of AI and machine learning technologies into healthcare systems. The voice-based analytics are being used for early detection of mental health conditions, cognitive impairment, and respiratory or cardiovascular disorders in hospitals, clinics, and research institutions. The non-invasive, cost-effective, and scalable diagnostic approach is thus accelerating the rate of adoption around the globe.
The growth potential of the vocal biomarkers market lies in integrations with digital health platforms, telemedicine solutions, or remote patient platforms. The vendors could create mobile applications or cloud services to evaluate Voice Data insights for early diagnosis of illnesses, mental health analysis, or managing chronic conditions. Partnerships between vendors, hospitals, insurance firms, or wellness platforms could generate new streams of revenues.
Share
Share
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients